XML 116 R51.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
manufacturer
item
Dec. 31, 2018
USD ($)
Concentration Risk [Line Items]    
Accounts receivable related to product sales $ 38,400 $ 23,100
Accounts receivable, net 42,744 37,211
Receivables from Collegium    
Concentration Risk [Line Items]    
Accounts receivable, net 4,104 $ 14,011
Collegium Pharmaceutical Inc | Commercialization Agreement    
Concentration Risk [Line Items]    
Prepaid and other current assets 1,500  
Collegium Pharmaceutical Inc | Commercialization Agreement | Receivables from Collegium    
Concentration Risk [Line Items]    
Accounts receivable, net $ 4,100  
Customer concentration risk | Consolidated revenue    
Concentration Risk [Line Items]    
Number of major distributors | item 3  
Gralise | Supplier concentration risk    
Concentration Risk [Line Items]    
Number of third-party contract manufacturers for the supply of gabapentin | manufacturer 1